{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:57:42Z","timestamp":1794743862024,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.<\/jats:p>","DOI":"10.1038\/s41408-022-00624-6","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T12:03:04Z","timestamp":1644494584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT)"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Arendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-8823","authenticated-orcid":false,"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-8855","authenticated-orcid":false,"given":"Theresa","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Kohlhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-297X","authenticated-orcid":false,"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-2886","authenticated-orcid":false,"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-335X","authenticated-orcid":false,"given":"David","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"624_CR1","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013346.","journal-title":"Lancet Oncol"},{"key":"624_CR2","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","volume":"20","author":"H Avet-Loiseau","year":"2020","unstructured":"Avet-Loiseau H, Ludwig H, Landgren O, Paiva B, Morris C, Yang H, et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20:e30\u2013e37.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"624_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0291-8","volume":"10","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar SK, et al. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer J. 2020;10:20.","journal-title":"Blood Cancer J"},{"key":"624_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9:102.","journal-title":"Blood Cancer J"},{"key":"624_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.75","volume":"7","author":"JR Mills","year":"2017","unstructured":"Mills JR, Barnidge DR, Dispenzieri A, Murray DL. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J. 2017;7:e590.","journal-title":"Blood Cancer J"},{"key":"624_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ajh.24772","volume":"92","author":"P Milani","year":"2017","unstructured":"Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92:772\u20139.","journal-title":"Am J Hematol"},{"key":"624_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","volume":"62","author":"JR Mills","year":"2016","unstructured":"Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62:1334\u201344.","journal-title":"Clin Chem"},{"key":"624_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00418-2","volume":"11","author":"BA Derman","year":"2021","unstructured":"Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021;11:19.","journal-title":"Blood Cancer J"},{"key":"624_CR9","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/JCO.2020.38.15_suppl.8512","volume":"38","author":"N Pu\u00edg","year":"2020","unstructured":"Pu\u00edg N, Contreras T, Paiva B, Cedena MT, Martinez-Lopez J, Oriol A, et al. Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS). J Clin Oncol. 2020;38:8512\u20138512.","journal-title":"J Clin Oncol"},{"key":"624_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37:589\u201397.","journal-title":"J Clin Oncol"},{"key":"624_CR11","doi-asserted-by":"crossref","unstructured":"Soh KT, Wallace PK. Monitoring of measurable residual disease in multiple myeloma by multiparametric flow cytometry. Curr Protoc Cytom. 2019;90:e63.","DOI":"10.1002\/cpcy.63"},{"key":"624_CR12","doi-asserted-by":"publisher","unstructured":"Tario JD, Wallace PK. Reagents and cell staining for immunophenotyping by flow cytometry. In: McManus LM, Mitchell RN, editors. Pathobiology of human disease. 1 ed. Elsevier, Academic Press; 2014. p. 3678\u2013701. https:\/\/doi.org\/10.1016\/B978-0-12-386456-7.07104-5.","DOI":"10.1016\/B978-0-12-386456-7.07104-5"},{"key":"624_CR13","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","volume":"38","author":"P Hari","year":"2020","unstructured":"Hari P, Pasquini MC, Stadtmauer EA, Fraser R, Fei M, Devine SM, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020;38:8506\u20138506.","journal-title":"J Clin Oncol"},{"key":"624_CR14","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","volume":"93","author":"RP Junghans","year":"1996","unstructured":"Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA. 1996;93:5512\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"624_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","volume":"29","author":"B Paiva","year":"2011","unstructured":"Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29:1627\u201333.","journal-title":"J Clin Oncol"},{"key":"624_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bjh.17195","volume":"193","author":"JP Abeykoon","year":"2021","unstructured":"Abeykoon JP, Murray DL, Murray I, Jevremovic D, Otteson GE, Dispenzieri A, et al. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. Br J Haematol. 2021;193:380\u20135.","journal-title":"Br J Haematol"},{"key":"624_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00473-9","volume":"11","author":"R Santockyte","year":"2021","unstructured":"Santockyte R, Jin C, Pratt J, Ammar R, Desai K, Bolisetty M, et al. Sensitive multiple myeloma disease monitoring by mass spectrometry. Blood Cancer J. 2021;11:78.","journal-title":"Blood Cancer J"},{"key":"624_CR18","doi-asserted-by":"publisher","first-page":"6933","DOI":"10.1002\/cam4.4254","volume":"10","author":"D Foureau","year":"2021","unstructured":"Foureau D, Bhutani M, Guo F, Rigby K, Leonidas M, Tjaden E. et al. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. Cancer Med. 2021;10:6933\u201336.","journal-title":"Cancer Med"},{"key":"624_CR19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","volume":"132","author":"JR Mills","year":"2018","unstructured":"Mills JR, Kohlhagen MC, Willrich MAV, Kourelis T, Dispenzieri A, Murray DL. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood. 2018;132:670\u20132.","journal-title":"Blood"},{"key":"624_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cca.2019.02.017","volume":"492","author":"LM Moore","year":"2019","unstructured":"Moore LM, Cho S, Thoren KL. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. Clin Chim Acta. 2019;492:91\u20134.","journal-title":"Clin Chim Acta"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00624-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00624-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00624-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:03:05Z","timestamp":1669233785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00624-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00624-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AD: Research dollars: Alnylam, Celgene\/BMS, Takeda, Pfizer; Consulting: Janssen, Oncopeptides and Regeneron. AK: Stock and Other Ownership Interests: Celgene (I), Kite Pharma (I); Consulting or Advisory Role: Celgene, Onyx, Janssen Oncology, Takeda, oncopeptides, and Regeneron; Speakers' Bureau: Celgene, Onyx, Janssen Oncology, Takeda; Research Funding: Janssen. BA: None. BB: Research dollars: Celgene (Inst), Takeda (inst). PKW: None. SD: Patent for mass spectrometry of blood immunoglobulins. DTV: Consulting or Advisory Role: Celgene, Amgen, Karyopharm Therapeutics, Teva, Janssen; Research Funding: Millennium (Inst), Acetylon Pharmaceuticals (Inst), GlaxoSmithKline (Inst), Calithera Biosciences (Inst), Constellation Pharmaceuticals (Inst); Travel, Accommodations, Expenses: Amgen. YE: Honoraria: Takeda; Speakers\u2019 bureau: Takeda, Janssen, Akcea. MF: None. NG: None. SG: Honoraria: Celgene, Takeda, Amgen, Jazz Pharmaceuticals, Sanofi; Consulting or Advisory Role: Celgene, Takeda, Sanofi, Jazz Pharmaceuticals, Amgen, Janssen; Research Funding: Celgene (Inst), Celgene (Inst), Takeda, Miltenyi Biotec (Inst), Johnson & Johnson, Amgen; Travel, Accommodations, Expenses: Celgene, Sanofi, Amgen, Jazz Pharmaceuticals. TH: None. AH: None. MK: None. HL: Consulting or Advisory Role: Celgene, Takeda, Caelum Biosciences, Juno Therapeutics; Research Funding: Takeda. PH: Honoraria: Celgene, Takeda, Sanofi, Amben, Spectrum pharmaceuticals, Novartis; Consulting or Advisory role: Celgene, Sanofi, Spectrum Pharmaceuticals, Takeda, Bristol-Myer Squibb, Janssen, Amgen; Research funding: Millennium (Inst), Celgene (Inst), Onyx (inst), Spectrum Pharmaceuticals (Inst). MCP: Honoraria: Celgene; Consulting or Advisory Role: Pfizer, Medigene (Inst). MHQ: Consulting or Advisory Role: Amgen; Speakers' Bureau: Merck, Sanofi; Research Funding: Amgen, Tesaro. PM: Honoraria: Celgene, Karyopharm Therapeutics, Bristol-Myers Squibb, Sanofi, Janssen, The Binding Site; Consulting or Advisory Role: Celgene, Bristol-Myers Squibb, Karyopharm Therapeutics, Sanofi, Janssen, The Binding Site, Magenta; Research Funding: Celgene (Inst). NS: Research Funding: Celgene\/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar; Advisory role: GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides. DHV: Stock and Other Ownership Interests: Amgen, AbbVie, Biogen, Gilead Sciences, Johnson & Johnson, Eli Lilly, Novartis; Honoraria: Amgen, Takeda; Speakers' Bureau: Amgen, Celgene, Janssen Oncology, Takeda. ES: Consulting or Advirory role: Celgene, Takeda, Novartis, Teva, Janssen, Amgen, Sanofi. DM: Patent for mass spectrometry of blood immunoglobulins.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}